Trial Outcomes & Findings for Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura (NCT NCT00601848)

NCT ID: NCT00601848

Last Updated: 2020-11-24

Results Overview

Toxicities of PDT as defined by CTCAE v4.0

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

9 participants

Primary outcome timeframe

One year

Results posted on

2020-11-24

Participant Flow

Participant milestones

Participant milestones
Measure
Photodynamic Therapy
PDT chemotherapy porfimer sodium immunohistochemistry staining method laboratory biomarker analysis spectroscopy therapeutic conventional surgery
Overall Study
STARTED
9
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
9

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Single Arm
n=9 Participants
PDT chemotherapy porfimer sodium immunohistochemistry staining method laboratory biomarker analysis spectroscopy therapeutic conventional surgery
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
n=5 Participants
Age, Categorical
>=65 years
6 Participants
n=5 Participants
Age, Continuous
71 years
STANDARD_DEVIATION 10.35 • n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=5 Participants
Race (NIH/OMB)
White
7 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
Region of Enrollment
United States
9 participants
n=5 Participants

PRIMARY outcome

Timeframe: One year

Population: The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported

Toxicities of PDT as defined by CTCAE v4.0

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 5 years

Population: The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported

Subject survival post PDT

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 5 years

Population: The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported

Amount of time from PDT to disease progression in pleura

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years

Population: The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported

Amount of time from PDT to disease progression at any site in the body

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 days

Population: The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported

Measured uptake of PDT drug

Outcome measures

Outcome data not reported

Adverse Events

Single Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Keith A Cengel, MD, PhD

University of Pennsylvania

Phone: (215) 615-5312

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place